All In Biotech

Drug Trial Radar · NCT01127451

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Last checked: Nov 20, 2026Latest source record: Apr 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Jun 22, 2010

Primary completion

Apr 7, 2015

Study completion Apr 7, 2015

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
PharmaBio Development Inc.
First posted
May 20, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.

Conditions

  • Stage IIIC Melanoma
  • Stage IV Melanoma

Interventions

  • Denileukin diftitoxDrug

    Denileukin diftitox intravenous infusion over 30-60 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Immune-related Overall Response Rate (irORR)Time frame: From the start of treatment up to 1 year 6 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Encinitas, California

  • Site not named

    Los Angeles, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Chicago, Illinois

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Detroit, Michigan

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Portland, Oregon

  • Site not named

    Amarillo, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.